TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes.

doi:10.1186/1471-2350-12-30

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes.

BMC medical genetics - 24 Feb 2011

Holstein Andreas, Hahn Michael, Körner Antje, Stumvoll Michael, Kovacs Peter

Abstract excerpt

BACKGROUND: Variants in the TCF7L2 have been shown to be associated with an increased risk for type 2 diabetes (T2D). Since the association with diabetes could be explained by effects on insulin secretion, we investigated whether patients with diabetes risk alleles at rs7903146 might have an altered hypoglycaemic response to sulfonylureas (SUs). METHODS: We recruited 189 patients with T2D being treated with SUs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Diabetes Mellitus, Type 2

Share to Hypoglycemic Agents

Share to Insulin

Share to Insulin Secretion

Share to Sulfonylurea Compounds

Share to Transcription Factor 7-Like 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 21349175
DOI: 10.1186/1471-2350-12-30
PMCID: PMC3051886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes.PMID 21349175Read ↗

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.Semantic proximity Read ↗

Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics.Semantic proximity Read ↗

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.Semantic proximity Read ↗

The Role of TCF7L2 in Type 2 Diabetes.Semantic proximity Read ↗

Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals.Semantic proximity Read ↗

Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population.Semantic proximity Read ↗

Prevalence of the rs7903146C>T polymorphism in TCF7L2 gene for prediction of type 2 diabetes risk among Iranians of different ethnicities.Semantic proximity Read ↗

The TCF7L2 rs7903146 (C/T) polymorphism is associated with risk to type 2 diabetes mellitus in Southern-Brazil.Semantic proximity Read ↗

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetesSemantic proximity Read ↗

Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.Semantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.